Open AccessPeak Inspiratory Flow Rate in COPD: An Analysis of Clinical Trial and Real-World Data
Author(s) -
Martin Anderson,
Kathryn Collison,
M. Bradley Drummond,
Melanie Hamilton,
Renu Jain,
Neil Martin,
Richard A. Mularski,
Mike Thomas,
ChangQing Zhu,
Gary T. Ferguson
Publication year - 2021
Publication title -
international journal of chronic obstructive pulmonary disease/international journal of copd
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 67
eISSN - 1178-2005
pISSN - 1176-9106
DOI - 10.2147/copd.s291554
Subject(s) - medicine , copd , dry powder inhaler , fluticasone propionate , budesonide , post hoc analysis , population , roflumilast , peak flow meter , clinical trial , formoterol , physical therapy , asthma , inhaler , environmental health
The influence of peak inspiratory flow (PIF) on dose delivery from dry powder inhalers (DPIs) and association with treatment efficacy in patients with chronic obstructive pulmonary disease (COPD) has not been fully determined. In vitro studies have demonstrated adequate dose delivery through ELLIPTA DPI at PIF ≥30 L/min. This analysis of two clinical trials and a real-world population of COPD patients determined spirometric PIF distribution, and explored the relationship between PIF and outcomes in the trials.